APP Pharmaceuticals, Inc, a leading manufacturer of multi-source and branded injectable pharmaceutical products, has launched Rocuronium Bromide Injection, the generic equivalent of Organon's Zemuron.

"In addition to safety measures such as barcoding and latex-free stoppers, APP has incorporated a peel off syringe label on all of its rocuronium vials," said Thomas H Silberg, president and chief executive officer of APP Pharmaceuticals. "Adding this feature to the vials enables healthcare facilities to comply with National Patient Safety Goal 3D, which requires labelling on all medications, syringes for perioperative and other procedural settings."

APP's rocuronium is AP-rated and preservative-free, and is marketed in two dosage forms, 50 mg/5mL and 100 mg/10 mL. One of the most widely used muscle relaxants in the United States, Canada and many European countries, according to IMS data, 20071 sales of rocuronium in the United States were approximately $127 million or 10 million units.

Used predominately in hospitals and clinics in general anaesthesia, rocuronium is an intravenous neuromuscular blocking agent (NMBA) that is administered during surgery to facilitate safe and rapid endotracheal intubation (insertion of a tube in the windpipe to facilitate artificial ventilation) and provide total skeletal muscle relaxation. Rocuronium is a nondepolarizing neuromuscular blocking agent that unlike other NMBA's provides immediate muscular relaxation.

APP Pharma is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anaesthetic/analgesic and critical care markets.

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific.

Fresenius SE is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.